Norgine completes acquisition of Merus Labs International

Norgine has announced the completion of its takeover of Merus Labs International, a specialty pharmaceutical company focused on acquiring and optimising legacy and growth products.

Based in Canada, Merus employs 22 people and has now become a wholly-owned subsidiary of Norgine, which has strengthened its position in the European specialist pharmaceutical market through this deal.

With the purchase of Merus, Norgine has gained access to a product portfolio of 12 established therapies, including Sintrom, Emselex, Elantan, Isoket, Deponit, Salagen and Estraderm, all of which are sold across Europe and other selected markets, as well as the Canada-exclusive Vancocin.

Merus' sales for the 2016 fiscal year came to C$111.4 million (68.09 million pounds), meaning it will be a valuable asset for Norgine. The company has pledged that patients will continue to receive the full range of Merus products through Norgine's European infrastructure.

Peter Stein, chief executive officer of Norgine, said: "This transaction increases Norgine's scale and profitability, helping to strengthen the business and attract new opportunities in the future."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.